Antibody-Mediated Thrombosis

• References

• 1 Vermylen J, Blockmans D, Spitz B, Deckmyn H. Thrombosis and immune disorders. Clin Haematol 1986; 15: 393-412
• 2 Carreras LO. Thrombosis and thrombocytopenia induced by heparin. Scand J Haematol 1980; (Suppl. 36) 64-80
• 3 Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 1973; 136: 409-416
• 4 Towne JB, Bernhard VM, Hussey C, Garancis JC. White-clot syndrome peripheral vascular complications of heparin therapy. Arch Surg 1979; 114: 372-377
• 5 Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet 02 1982; 1246-1249
• 6 Kappa JR, Fisher CA, Addonizio Jr VP. Heparin-induced platelet activation: the role of thromboxane A2 synthesis and the extent of platelet granule release in two patients. J Vase Surg 09 1989; 574-579
• 7 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin- induced thrombocytopenia. Blood 1986; 67: 27-30
• 8 Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-3699
• 9 Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-930
• 10 Chong BH, Castaldi PA, Berndt MC. Heparin-induced thrombocytopenia: effects of rabbit IgG, and its Fab and Fc fragments on antibody-heparin-platelet interaction. Thromb Res 1989; 55: 291-295
• 11 De ReysS, Blom C, Lepoudre B, Declerck PJ, De LeyM, Vermylen J, Deckmyn H. Human platelet aggregation by murine monoclonal antiplatelet antibodies is subtype-dependent. Blood 1993; 81: 1792-1800
• 12 Warmerdam PAM, van deWinkel JGJ, Vlug A, Westerdaal NAC, Capel PJA. A single amino acid in the second Ig-like domain of the Fcg receptor II is critical for human IgG2 binding. J Immunol 1991; 147: 1338-1343
• 13 Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet FcgRIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-1572
• 14 Arepally G, Poncz M, McKenzie SE, Cines D. Characterization of antibody subclass specificity and antigenic determinants in heparin-associated thrombocytopenia. Blood 1994; 84: 189 a
• 15 McCree KR, Shattil SJ, Cines DB. Platelet activation induces increased Fc gamma receptor expression. J Immunol 1990; 144: 3920-3927
• 16 Chong BH, Pilgrim RL, Cooley MA, Chesterman CN. Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. Blood 1993; 81: 988-993
• 17 Green D, Harris K, Reynolds N, Roberts M, Patterson R. Heparin immune thrombocytopenia: evidence for a heparin- platelet complex as the antigenic determinant. J Lab Clin Med 1978; 91: 167-175
• 18 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67: 545-549
• 19 Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinand E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96
• 20 Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239
• 21 Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-251
• 22 Brandt JT. Platelet aggregation in heparin-induced thrombocytopenia is dependent on complement activation. Blood 1996; 88: 517 a
• 23 Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88
• 24 Cines DB, Tomaski A, Tannenbaum S. Immune endothelialcell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581-589
• 25 Ikeda K, Nagasawa K, Hiriuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394-398
• 26 Boshkov LKWarkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-328
• 27 Feinstein PG, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb 1972; 01: 75-95
• 28 Frick PG. Acquired circulating anticoagulants in systemic “collagen disease”. Auto-immune thromboplastin deficiency. Blood 1995; 10: 691-706
• 29 Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR. Anticoardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 02: 1211-1244
• 30 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme- linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-744
• 31 Bowie EJW, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
• 32 Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (antithromboplastin). Acta Med Scand 1975; 197: 153-159
• 33 Soulier JP, Boffa MC. Avortements à répétitition, thromboses et anticoagulant circulant antithromboplastin. Trois observations. Nouv Press Médicale 1980; 09: 859-864
• 34 De Wolf F, Carreras LO, Moerman PH, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829-834
• 35 Harris EN, Baguley E, Asherson RA, Hughes GRV. Clinical and neurological features of the antiphospholipid syndrome (APS). Br J Rheumatol 1987; 26: 19
• 36 Asherson RA. A “primary” antiphospholipid syndrome ?. J Rheumatol 1988; 15: 1742-1746
• 37 Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 01: 244-246
• 38 Comp PC, De Bault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62 (Suppl. 01) 299
• 39 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
• 40 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
• 41 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
• 42 Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992; 67: 499-502
• 43 Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90: 1100-1104
• 44 Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300
• 45 Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize b 2-Glycoprotein I structure altered by interaction with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462
• 46 Ichikawa Y, Takamatsu K, Shimizu H, Uchiyama M, Moriuchi J, Takaya M, Kobayashi N, Kawada T, Arimori S. Serum apolipoprotein H levels in systemic lupus erythematosus are not influenced by antiphospholipid antibodies. Lupus 1992; 01: 145-149
• 47 Bancsi LF, van der Linden IK, Bertina RM. b₂-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649-653
• 48 Galli M, Bevers EM. Inhibition of phospholipid-dependent coagulation reactions by “antiphospholipid antibodies:l possible modes of action. Lupus 1994; 03: 223-238
• 49 Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis A study of 25 cases and review of the literature. Haemostasis, 1985; 15: 154-162
• 50 Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abbott TM, Hammond EH, Daynes RA. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210-216
• 51 Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88: 3069-3073
• 52 Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, Allegri F, Balestrieri G, Valesini G, Shoenfeld Y. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994; 07: 441-455
• 53 Arvieux J, Pouzol P, Roussel B, Jacob MC, Colomb MG. Lupus-like anticoagulant properties of murine monoclonal antibodies to b 2-glycoprotein I. Br J Haematol 1992; 81: 568-573
• 54 Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I. Thromb Haemost 1993; 70: 336-341
• 55 Arvieux J, Jacob MC, Roussel B, Bensa JC, Colomb MG. Neutrophil activation by anti-b₂glycoprotein I monoclonal antibodies via Fcg receptor II. J Leukoc Biol 1995; 57: 387-394
• 56 Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536-541
• 57 Simantov R, Gharavi A, Casali P, Lo SK, Salmon JE, Sammaritano LR, Silverstein RL. Activation of vascular endothelial cells by murine and human monoclonal anticoardiolipin antibodies. Blood 1996; 88 (Suppl. 01) 510 a
• 58 Olee T, Pierangeli SS, Handley HH, Le DT, Wei X, Lai CJ, En J, Novotny W, Harris EN, Woods Jr VL, Chen PP. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci USA 1996; 93: 8606-8611
• 59 Rosove MH, Brewer PM. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308
• 60 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997
• 61 Hasselaar P, Derksen RH, Oosting JD, Blokzijl L, de GrootPG. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemost 1989; 62: 654-660
• 62 Shi W, Chong BH, Chesterman CN. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81: 1255-1262
• 63 Willems GM, Janssen MP, Pelsers MMAL, Confurius P, Galli M, Zwaal RFA, Bevers EM. Role of divalency in the high-affin- ity binding of anticardiolipin antibody-b₂-glycprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-13842
• 64 Chamley LW, Pattison NS, McKay EJ. Elution of anticardiolipin antibodies and their cofactor b 2-glycoprotein I from placentae of patients with a poor obsteric history. J Reprod Immunol 1993; 25: 209-220
• 65 La RosaL, Meroni PL, Tincani A, Balestrieri G, Faden D, Lojacono A, Morassi L, Brocchi E, Del PapaN, Gharavi A, Sammaritano L, Lockshin M. b 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J Rheumatol 1994; 21: 1684-1693
• 66 Nomura S, Yanabu M, Miyake T, Miyazaki Y, Kido H, Kagawa H, Fukuhara S, Komiyama Y, Matsuura E, Koike T. Relationship of microparticles with b 2-glycoprotein I and P-selectin positivity to anticardiolipin antibodies in immune thrombocytopenic purpura. Ann Hematol 1995; 70: 25-30
• 67 Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-924
• 68 Arvieux J, Roussel B, Ponard D, Colomb MG. IgG2 subclass restriction of anti-b₂glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-315
• 69 Reverter JC, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M, Ordinas A. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscl Thromb Vase Biol 1996; 16: 1319-1326
• 70 Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest 1979; 63: 147-150
• 71 Hoylaerts MF, Arnout J, Thys C, Vermylen J. Auto-antibodies induce von Willebrand factor mediated platelet activation via immune complex formation in a patients with recurrent thrombosis. Thromb Haemost. 1997. 78. suppl 01 abstract this congress
• 72 Tornai I, Arnout J, Deckmyn H, Peerlinck K, Vermylen J. A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein Ib - and IIb/IIIa- binding domains. J Clin Invest 1993; 91: 273-282
• 73 Vermylen J, Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phos-pholipid-protein complexes. J Lab Clin Med 1992; 120: 10-12